Lido Advisors LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Lido Advisors LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,417 shares of the biopharmaceutical company’s stock after buying an additional 1,271 shares during the period. Lido Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $10,356,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Sound Shore Management Inc. CT lifted its position in shares of Regeneron Pharmaceuticals by 52.9% in the fourth quarter. Sound Shore Management Inc. CT now owns 175,887 shares of the biopharmaceutical company’s stock worth $135,762,000 after buying an additional 60,859 shares in the last quarter. Anchor Capital Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals by 6.0% in the fourth quarter. Anchor Capital Advisors LLC now owns 12,499 shares of the biopharmaceutical company’s stock worth $9,648,000 after buying an additional 702 shares in the last quarter. CIBC Asset Management Inc lifted its position in shares of Regeneron Pharmaceuticals by 31.9% in the fourth quarter. CIBC Asset Management Inc now owns 42,667 shares of the biopharmaceutical company’s stock worth $32,933,000 after buying an additional 10,329 shares in the last quarter. Mccarter Private Wealth Services LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $202,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Regeneron Pharmaceuticals by 13.8% in the fourth quarter. Bank of New York Mellon Corp now owns 764,242 shares of the biopharmaceutical company’s stock worth $589,896,000 after buying an additional 92,612 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research analyst reports. Royal Bank Of Canada decreased their target price on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating on the stock in a research report on Monday, May 18th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $800.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. Canaccord Genuity Group decreased their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Leerink Partners reiterated a “market perform” rating and issued a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. Finally, Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $792.65.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron expanded its cancer therapy partnership with CytomX Therapeutics, a deal that could generate up to $4 billion in potential milestones and broadens its bispecific oncology pipeline. REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
• Positive Sentiment: The company also reported highly favorable Lynozyfic trial results in light chain amyloidosis, which supports the view that Regeneron’s clinical pipeline may have additional upside. A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
• Positive Sentiment: Regeneron said it will highlight new data from its metabolic disease, ophthalmology and rare disease programs at upcoming ADA and ENDO meetings, giving investors another near-term catalyst to watch. Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
• Neutral Sentiment: Parabilis Medicines, a Regeneron-partnered biotech, is pursuing an IPO to advance zolucatetide into Phase III, which could indirectly reflect on Regeneron’s partner network but does not directly change REGN’s fundamentals. Parabilis eyes $475m IPO to push lead asset into Phase III
• Negative Sentiment: An investor alert from Pomerantz LLP announced an investigation into claims on behalf of Regeneron shareholders, which may create some legal overhang and weigh on sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the sale, the director directly owned 17,503 shares in the company, valued at $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Trading Up 1.1%

Shares of REGN stock opened at $635.45 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $485.00 and a 1 year high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The stock’s 50 day simple moving average is $706.93 and its two-hundred day simple moving average is $742.16. The company has a market cap of $67.18 billion, a PE ratio of 15.48, a price-to-earnings-growth ratio of 1.38 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same period in the prior year, the business posted $8.22 earnings per share. The company’s quarterly revenue was up 19.0% compared to the same quarter last year. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a dividend of $0.94 per share. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.